PHILADELPHIA, April 3 /PRNewswire-FirstCall/ -- Based on the unanimous recommendation of an Independent Data Monitoring Committee (IDMC), GlaxoSmithKline announced today that it has halted enrollment in its Phase III clinical trial evaluating the combination of Tykerb (lapatinib ditosylate) and capecitabine (Xeloda(R)) versus capecitabine alone. The trial evaluated women with refractory advanced or metastatic breast cancer who have documented ErbB2 (HER2) overexpression and whose disease progressed following treatment with trastuzumab (Herceptin(R)) as well as other cancer therapies. A pre-planned interim analysis of 321 patients in the study yielded statistically significant results, exceeding the primary endpoint.
According to the study protocol, the pre-planned interim analysis was reviewed by the IDMC, which is comprised of medical oncology experts and a statistician. The IDMC unanimously recommended halting enrollment in the study because it exceeded its primary endpoint of time to disease progression, or TTP, for women receiving the combination of Tykerb and capecitabine. The IDMC made their recommendation based on pre-specified stopping rules outlined in their charter. All women currently enrolled in the trial will continue to be followed and those who are receiving capecitabine alone will be offered the option of switching to the combination therapy of capecitabine and Tykerb in consultation with their physician.
“We are extremely encouraged by these data which suggest that Tykerb may offer significant benefit as an oral medication in combination with chemotherapy for patients with advanced or metastatic ErbB2 positive breast cancer, and whose disease has progressed on previous treatment regimens, including Herceptin,” said Paolo Paoletti, M.D., Senior Vice President of the Oncology Medicine Development Center, at GSK. “On the basis of this and other data we now plan to file in the US and Europe during the second half of 2006.”
The Phase III trial (EGF100151) is an international, multi-center, randomized, open-label study to evaluate and compare TTP in patients with documented ErbB2 (HER2) overexpressing refractory advanced or metastatic breast cancer treated with Tykerb in combination with capecitabine versus capecitabine alone. The primary endpoint of the study was to detect a 50 percent increase in TTP in the combination arm compared with the capecitabine alone arm. 392 patients have been enrolled in the study of which 321 were included in the analysis (160 in the combination arm and 161 in the monotherapy arm). The most common drug-related adverse events in the combination arm of the study were diarrhea and nausea.
Tykerb is an experimental drug that does not have regulatory approval in any country for any use outside of clinical trials.
About Metastatic Breast Cancer
The World Health Organization reports that just over one million cases of breast cancer are diagnosed annually. Breast cancer is the most common non- cutaneous malignancy in women and one of the leading causes of cancer death.
Approximately 10-20 percent of newly diagnosed breast cancer patients have locally advanced and/or metastatic disease; 20 to 85 percent of patients (depending on initial stage, tumor biology, and treatment strategy) diagnosed with early breast cancer will develop recurrent and/or metastatic disease. The median survival time for women treated for metastatic breast cancer is two years.
About Tykerb
Tykerb, a small molecule that is administered orally, inhibits the tyrosine kinase components of ErbB1 and ErbB2 receptors. Stimulation of ErbB1 and ErbB2 is associated with cell proliferation and with multiple processes involved in tumor progression, invasion, and metastasis. Overexpression of these receptors has been reported in a variety of human tumors and is associated with poor prognosis and reduced overall survival. GSK is using advanced technologies, including pharmacogenetics, to better define patient populations that may respond to Tykerb.
Tykerb is being developed by GSK as an orally administered therapy for breast cancer and other solid tumors.
GlaxoSmithKline is one of the world’s leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
GlaxoSmithKline
CONTACT: Inquiries: US Media inquiries: Nancy Pekarek, +1-215-751-7709, orMary Anne Rhyne, +1-919-483-2839, or Patty Seif, +1-215-751-7709, or GaileRenegar, +1-215-751-7709; or UK Media inquiries: Phil Thomson, DavidMawdsley, Chris Hunter-Ward, or Alice Hunt, (020) 8047 5502; or USAnalyst/Investor inquiries: Frank Murdolo, +1-215-751-7002, or Tom Curry,+1-215-751-5419; or European Analyst/Investor inquiries: Duncan Learmouth,(020) 8047 5540, or Anita Kidgell, (020) 8047 5542, or Jen Hill, (020) 80475543, all of GlaxoSmithKline
Web site: http://www.gsk.com/
Company News On-Call: http://www.prnewswire.com/comp/801350.html/
